タナカ ヨシオ
Tanaka Yoshio
田中 芳夫 所属 東邦大学 薬学部 薬学科 職種 教授 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Acute effects of intravenous administration of polyunsaturated fatty acids on blood pressure and heart rate in U46619- and noradrenaline-infused rats. |
掲載誌名 | 正式名:British Journal of Pharmaceutical Research 略 称:Br J Pharmaceu Res ISSNコード:22312919 |
掲載区分 | 国外 |
出版社 | SCIENCEDOMAIN international |
巻・号・頁 | 15(3),pp.1-12 |
著者・共著者 | Chino D†, Yuda S†, Suzuki Y†, Hatsuyama F†, Sato K, Obara K†, Tanaka Y* |
担当区分 | 最終著者,責任著者 |
発行年月 | 2017/03 |
概要 | Experimental studies and epidemiological surveys have indicated that chronic oral administration of the n-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic (DHA) or eicosapentaenoic (EPA) acids reduces blood pressure in hypertensive patients. However, few reports have described the acute blood pressure lowering effects of these PUFAs. In this study, we determined the acute effects of DHA and EPA on blood pressure of rats with increased blood pressure resulting from continuous injection of pressor substances. U46619 (a TXA2 receptor agonist) and noradrenaline (NA) were continuously infused (500 μg/kg/h each) into urethane-anesthetized male Wistar rats and produced sustained elevated mean blood pressure (MBP). In both U46619- and NA-infused rats, bolus administration of DHA (3–30 mg/kg, i.v.) reduced blood pressure in a dose-dependent manner, although the MBP reduction was greater in U46619-infused rats. Similarly, administration of EPA (3–30 mg/kg, i.v.) also induced a greater reduction in MBP of U46619-infused rats. In contrast, bolus administration of linoleic acid (3–30 mg/kg, i.v.), an n-3 type unsaturated fatty acid, failed to reduce blood pressure in all drug-infused rats. Finally, administration of the nitric oxide donor sodium nitroprusside (0.3–100 μg/kg, i.v.) showed a similar blood pressure drop in all drug-infused rats. These findings clearly indicate that both DHA and EPA induce acute blood pressure reduction in anesthetized rats, and suggest that the blood pressure drop is mediated via the TXA2 receptor. These characteristic blood pressure lowering effects of these PUFAs are likely to be useful for prevention and treatment of hypertension. |